Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Episodes of depression are the most frequent cause of disability among patients with bipolar disorder. The effectiveness and safety of standard antidepressant agents for depressive episodes associated with bipolar disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania. Methods In this double-blind, placebo-controlled study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to routine clinical care. A standardized clinical monitoring form adapted from the mood-disorder modules of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, was used at all follow-up visits. The primary outcome was the percentage of subjects in each treatment group meeting the criterion for a durable recovery (8 consecutive weeks of euthymia). Secondary effectiveness outcomes and rates of treatment-emergent affective switch (a switch to mania or hypomania early in the course of treatment) were also examined. Results Forty-two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy had a durable recovery, as did 51 of the 187 subjects (27.3%) receiving a mood stab…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on negative placebo‐controlled data, we do not recommend paroxetine (level 2 negative).245”
In the citing paper
“Antimanic medications reduce depressive symptoms in only one-third of patients (2).”
From Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial (2018) · cites this paper as [2]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Self-citationPrevalence and Treatment of Mental Disorders
(2005) · New England Journal of Medicine · doi:10.1056/nejmc051936 · Cited by 650
Scott, J., Paykel, E., Morriss, R., Bentall, R., Kinderman, P., Johnson, T., Abbott, R., & Hayhurst, H. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.313 · Cited by 566
Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Gijsman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1537 · Cited by 563
Sachs, G. S., Thase, M. E., Otto, M. W., Bauer, M., Miklowitz, D., Wisniewski, S. R., Lavori, P., Lebowitz, B., Rudorfer, M., Frank, E., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00165-3 · Cited by 533
Self-citationThe global burden of disease in 1990: summary results, sensitivity analysis and future directions.
Murray, C. J. L., López, A. D., & Jamison, D. T. T. (1994) · Europe PMC (PubMed Central) · Cited by 518
Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T., McElroy, S. L., Keck, P. E., Kupka, R. W., Denicoff, K. D., Nolen, W. A., Grunze, H., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.232 · Cited by 419
Post, R. M., Denicoff, K. D., Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T. M., Rush, A. J., Keck, P. E., McElroy, S. L., Luckenbaugh, D. A., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0610 · Cited by 418
Nemeroff, C. B., Evans, D. L., Gyulai, L., Sachs, G. S., Bowden, C. L., Gergel, I. P., Oakes, R., & Pitts, C. D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.906 · Cited by 407
Self-citationGoodwin, G. M. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017002003 · Cited by 390
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., Suppes, T., McElroy, S., Keck, P. E., Denicoff, K. D., et al. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.013045 · Cited by 350
Suppes, T., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 330
Self-citationA double-blind trial of bupropion versus desipramine for bipolar depression.
Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M. D., Thibault, A., Tohen, M. F., & Rosenbaum, J. F. (1994) · PubMed · Cited by 272
Self-citationVieta, E., Martinez-Aran, A., Goikolea, J. M., Torrent, C., Colom, F., Benabarre, A., & Reinares, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0607 · Cited by 227
Simon, G. E., & Unützer, J. (1999) · Psychiatric Services · doi:10.1176/ps.50.10.1303 · Cited by 145
A clinical monitoring form for mood disorders
Sachs, G. S., Guille, C., & McMurrich, S. L. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01195.x · Cited by 142
Self-citationAdjunctive psychotherapy for bipolar disorder: Effects of changing treatment modality.
Frank, E., Swartz, H. A., Mallinger, A. G., Thase, M. E., Weaver, E. V., & Kupfer, D. J. (1999) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.108.4.579 · Cited by 123
Self-citationPharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants
Ghaemi, S. N., Hsu, D. J., Thase, M. E., Wisniewski, S. R., Nierenberg, A. A., Miyahara, S., & Sachs, G. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.5.660 · Cited by 121
Self-citationSuicidal Ideation and Pharmacotherapy Among STEP-BD Patients
Goldberg, J. F., Allen, M. H., Miklowitz, D. A., Bowden, C. L., Endick, C. J., Chessick, C. A., Wisniewski, S. R., Miyahara, S., Sagduyu, K., Thase, M. E., et al. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.12.1534 · Cited by 37
Self-citation
Research works printed but not linked: 4
- Murray CJ, 1994, Bull World Health Organ, 72, 495
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Sachs GS, 1994, J Clin Psychiatry, 55, 391
- 10.1037/0021-843X.108.4.579 · doi:10.1037/0021-843x.108.4.579 · Paper page
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“Further, several small crossover trials demonstrated significantly higher response rates to lithium than placebo in patients with acute bipolar depression (245).”
BackgroundSelf-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“compared paroxetine and bupropion with placebo and the results were certainly negative (Sachs et al., 2007).”
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
“For instance, OFC was shown to be more effective than placebo or olanzapine monotherapy (93, 95), but the combination of paroxetine or bupropion with a mood stabilizer was not more effective than a mood stabilizer plus placebo (124).”
BackgroundWisner, K. L., Sit, D. K. Y., McShea, M. C., Rizzo, D. M., Zoretich, R. A., Hughes, C. L., Eng, H. F., Luther, J. F., Wisniewski, S. R., Costantino, M. L., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.87 · Cited by 1,091
“Treatment of the depressed phase of bipolar disorder with a mood stabilizer and an antidepressant does not confer benefit beyond treatment with a mood stabilizer alone.(60) Given the critical importance of birth as a life event for families, detection and treatment of bipolar disorder among childbearing women has majo…”
BackgroundSelf-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
“Compared with our previous study with ketamine in patients with treatment-resistant major depressive disorder,(34) we found (1) more rapid onset of antidepressant effects (40 vs 110 minutes), (2) a higher response rate at 40 minutes (56% vs 11%) but lower at day 1 (42% vs 71%), (3) similar remission rates at day 1 (31…”
Result
Metadata
- Authors
- Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- Baylor College of Medicine (US)
- University of Pittsburgh (US)
- University of Pennsylvania (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Oklahoma (US)
- Stanford Medicine (US)
- University of Massachusetts Chan Medical School (US)
- University of Toledo (US)
- University of Colorado Boulder (US)
- Boston University (US)
- Purdue University West Lafayette (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-26
- Volume
- 356
- Issue
- 17
- Pages
- 1711-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166423384
- Semantic Scholar
- c224a40d0ffd6471e7b72b38060d169ba1cdec34
- Cited by
- 937
- References
- 27
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 33 · 2023: 17 · 2022: 15 · 2021: 68 · 2020: 33 · 2019: 29 · 2018: 36 · 2017: 28 · 2016: 53 · 2015: 47 · 2014: 51 · 2013: 52 · 2012: 61
- FWCI
- 56.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh80001-12-0-0)
- National Institute of Mental Health (N01-MH80001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- bipolar depression, adjunctive antidepressant therapy, mood stabilizers, euthymia, bipolar disorder, antidepressant safety
- MeSH terms
- Adult, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Bupropion, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.